Kazia Therapeutics (KZIA) announced its intention to request and hold a follow-up Type C meeting with the U.S. Food & Drug Administration to discuss overall survival findings in newly diagnosed glioblastoma patients treated with paxalisib and to seek agency feedback on a potential regulatory pathway aligned with the FDA Oncology Center of Excellence’s Project FrontRunner initiative.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KZIA:
- Strategic Advancements and Potential in Oncology: Kazia Therapeutics’ Buy Rating Driven by Novel PD-L1 Degrader and AI-Driven Paxalisib Development
- Kazia Therapeutics Partners with QIMR Berghofer for Innovative PD-L1 Degrader Program
- Kazia Therapeutics signs collaboration and in-licensing agreement for PD-L1
- Kazia Therapeutics Reports Significant Tumor Reduction in TNBC Patient with Paxalisib
- Kazia Therapeutics price target raised to $20 from $15 at Maxim